Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia
HALOPERIDOL may leads to higher adverse effects ‐ movement disorders ‐ At least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
HALOPERIDOL probably leads to lower adverse effects ‐ other ‐ Sedation compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
1 finding from 1 review
Death · patients with schizophrenia
1 finding from 1 review
Quality of life · patients with schizophrenia
1 finding from 1 review
Death: Suicide and natural causes (no data) · patients with schizophrenia
1 finding from 1 review
Global state: no overall improvement (psychiatrist ‐ rated) · patients with schizophrenia
HALOPERIDOL probably leads to lower overall improvement: No marked global improvement Rated by clinician compared with PLACEBO (moderate certainty).
1 finding from 1 review
Not discharged from hospital · patients with schizophrenia
It is very uncertain whether HALOPERIDOL changes not discharged from hospital compared with PLACEBO (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether HALOPERIDOL changes relapse compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
HALOPERIDOL showed no clear difference in leaving the study early compared with PLACEBO (moderate certainty).
1 finding from 1 review
Satisfaction with treatment · patients with schizophrenia
1 finding from 1 review
Adverse effects. Specific: movement disorders ‐ parkinsonism · patients with schizophrenia
HALOPERIDOL probably leads to higher adverse effects: Movement disorders ‐ parkinsonism compared with PLACEBO (moderate certainty).
1 finding from 1 review
Tranquil or asleep: Not tranquil or asleep ‐ by 30 mins · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE leads to lower tranquil or asleep: Not tranquil or asleep ‐ by 30 minutes compared with ANTIPSYCHOTIC ‐ HALOPERIDOL (high certainty).
1 finding from 1 review
Adverse effects: Specific and serious adverse effect ‐ by 24 hours Central nervous system ‐ excessive sedation · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in adverse effects: Specific and serious adverse effects by 24 hours… compared with ANTIPSYCHOTIC ‐ OLANZAPINE (low certainty).
1 finding from 1 review
Adverse effect: Specific ‐ Death · people with psychosis‐induced aggression
1 finding from 1 review
Service outcomes: Not discharged ‐ by 4 hours · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in service outcomes: Not discharged ‐ by 4 hours compared with ANTIPSYCHOTIC ‐ OLANZAPINE (high certainty).
1 finding from 1 review
Aggression · people with psychosis‐induced aggression
1 finding from 1 review
Economic outcomes: Cost of care · people with psychosis‐induced aggression
1 finding from 1 review
Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · people with psychosis‐induced aggression
1 finding from 1 review
Global state: Needing restraints or seclusion ‐ by 12 hours · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in global state: Needing restraints or seclusion ‐ by 12 hours compared with ANTIPSYCHOTIC ‐ ZIPRASIDONE (moderate certainty).
1 finding from 1 review
Adverse effects: Specific and serious adverse effect ‐ by 24 hours Central nervous system ‐ excessive sedation · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in adverse effects: Specific and serious adverse effect ‐ by 24 hours… compared with ANTIPSYCHOTIC ‐ ZIPRASIDONE (low certainty).
1 finding from 1 review